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Abstract
Background: Huntington’s disease (HD) is a progressive neurodegenerative disorder caused by a polyglutamine
expansion in the Huntingtin protein which results in the selective degeneration of striatal medium spiny neurons
(MSNs). Our group has previously demonstrated that calcium (Ca
2+) signaling is abnormal in MSNs from the yeast
artificial chromosome transgenic mouse model of HD (YAC128). Moreover, we demonstrated that deranged
intracellular Ca
2+ signaling sensitizes YAC128 MSNs to glutamate-induced excitotoxicity when compared to wild
type (WT) MSNs. In previous studies we also observed abnormal neuronal Ca
2+ signaling in neurons from
spinocerebellar ataxia 2 (SCA2) and spinocerebellar ataxia 3 (SCA3) mouse models and demonstrated that
treatment with dantrolene, a ryanodine receptor antagonist and clinically relevant Ca
2+ signaling stabilizer, was
neuroprotective in experiments with these mouse models. The aim of the current study was to evaluate potential
beneficial effects of dantrolene in experiments with YAC128 HD mouse model.
Results: The application of caffeine and glutamate resulted in increased Ca
2+ release from intracellular stores in
YAC128 MSN cultures when compared to WT MSN cultures. Pre-treatment with dantrolene protected YAC128
MSNs from glutamate excitotoxicty, with an effective concentration of 100 nM and above. Feeding dantrolene (5
mg/kg) twice a week to YAC128 mice between 2 months and 11.5 months of age resulted in significantly
improved performance in the beam-walking and gait-walking assays. Neuropathological analysis revealed that long-
term dantrolene feeding to YAC128 mice significantly reduced the loss of NeuN-positive striatal neurons and
reduced formation of Htt
exp nuclear aggregates.
Conclusions: Our results support the hypothesis that deranged Ca
2+ signaling plays an important role in HD
pathology. Our data also implicate the RyanRs as a potential therapeutic target for the treatment of HD and
demonstrate that RyanR inhibitors and Ca
2+ signaling stabilizers such as dantrolene should be considered as
potential therapeutics for the treatment of HD and other polyQ-expansion disorders.
Keywords: Huntington?’?s disease, calcium signaling, calcium imaging, cell death, dantrolene, ryanodine receptor,
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Background
Huntington’s disease (HD) is an autosomal-dominant
inherited neurological disorder characterized by abnor-
mal involuntary movements (chorea, dystonia and bra-
dykinesia) cognitive dysfunction, and psychiatric
disturbance. At the molecular level, the cause of HD is a
mutation in the cytosolic huntingtin (Htt) protein
resulting in the expansion of a polyglutamine (polyQ)-
repeat at the amino-terminus. Experimental evidence
indicates that the polyQ expansion in mutant Htt
(Htt
exp)l e a d st oa“toxic gain or loss of function”,l e a d -
ing to the progressive and selective death of striatal
medium spiny neurons (MSNs) [1,2]. However, the cel-
lular mechanisms underlying the cause of MSN degen-
eration are not clear. Our previous studies demonstrated
that deranged calcium (Ca
2+) release from the endoplas-
mic reticulum (ER) was caused by a direct association of
Htt
exp with the type 1 inositol 1, 4, 5- trisphosphate
receptor (InsP3R1) [3], leading to apoptosis in MSNs
[4]. In addition, over-expression of the cytosolic car-
boxy-terminus region of InsP3R1 (IC10 fragment) dis-
rupted the Htt
exp-InsP3R1 interaction and prevented the
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demonstrated pathological enhancement of neuronal
store-operated Ca
2+ entry (SOC) pathway in HD [6]. In
addition, increased Ca
2+ influx via extrasynaptic NR2B
subunit of N-methyl-D-aspartate receptor (NMDAR)
was proposed to play an important role in excitotoxic
cell death of HD MSN neurons [4,7-12]. Collectively
these data indicate that Ca
2+ signaling plays an impor-
tant role in the pathogenesis of HD [13-16].
The mechanisms of Ca
2+ release from intracellular
stores involves several pathways, including InsP3-
induced Ca
2+ release (IICR) mediated by the InsP3Rs
and Ca
2+-induced Ca
2+ release (CICR) triggered by the
ryanodine receptors (RyanR). Because Ca
2+ release by
IICR is often amplified by CICR [17] and augmented
release of Ca
2+ from intracellular stores were toxic to
HD MSNs [4,5], we reasoned that inhibiting RyanR-
mediated CICR and stabilizing Ca
2+ signaling would
have neuroprotective effects in YAC128 HD mice. We
have shown previously that the RyanR antagonist and
clinically relevant intracellular Ca
2+ stabilizer, dantro-
lene, was neuroprotective in mouse models of spinocer-
ebellar ataxia type 2 (SCA2) and type 3 (SCA3) [18,19],
attenuating glutamate-induced apoptosis of cultured
SCA2-58Q Purkinje cells. Furthermore, feeding dantro-
lene to both SCA2-58Q and SCA3-YAC-84Q mice pre-
vented neuronal cell loss and improved motor deficits
[18,19]. In the present study we discovered that dantro-
lene pre-treatment protected cultured YAC128 MSNs
from glutamate-induced apoptosis. In addition, feeding
dantrolene to YAC128 mice significantly alleviated age-
dependent motor deficits developed by YAC128 mice,
reduced the death of NeuN-positive striatal neurons and
inhibited nuclear aggregation of Htt
exp. These results
suggest that inhibiting RyanR-mediated CICR is a feasi-
ble therapeutic approach for the treatment of HD and
that dantrolene is a potential agent that can be used for
this purpose.
Results
Caffeine potentiates Ca
2+ release induced by glutamate in
YAC128 MSNs
Previous studies demonstrated that glutamate treatment
induces supranormal Ca
2+ responses in MSNs from HD
mice [3-5,7]. To investigate whether RyanR-mediated
CICR can contribute to the total Ca
2+ response of
YAC128 MSNs to glutamate, we compared Ca
2+
responses induced by glutamate, the RyanR agonist caf-
feine, and the simultaneous application of glutamate and
caffeine in WT and YAC128 MSNs at 10 days in vitro
(DIV). The intracellular Ca
2+ levels were continuously
monitored by Fura-2 imaging and quantitatively deter-
mined by the 340/380 nm ratio, where an increase in
the ratio indicated an increase in intracellular Ca
2+
levels. The changes in intracellular Ca
2+ levels was cal-
culated as the difference between the basal 340/380 nm
value prior to glutamate and/or caffeine treatment and
the peak value at the completion of the treatment in the
same cell. We observed that after the application of 2.5
μM glutamate, the peak 340/380 nm value in YAC128
MSNs was not significantly different compared to WT
MSNs (Figure 1A, D). Also, the addition of 2.5 mM caf-
feine alone did not cause a significant increase in 340/
380 nm values in either YAC128 or WT MSNs (Figure
1B, D). However, when cells were treated with glutamate
and caffeine together there was a significant increase in
the 340/380 nm ratios as compared to glutamate treat-
ment alone in both YAC128 and WT MSNs, suggesting
that caffeine treatment can sensitize the intracellular
Ca
2+ response to glutamate in MSNs (Figure 1C).
Furthermore, the peak responses of YAC128 MSNs to
glutamate and caffeine mixture were significantly higher
(p < 0.05) than in WT MSNs (Figures 1C, D). These
data demonstrate that CICR from RyanR-gated stores is
significantly increased in YAC128 MSNs compared to
WT when challenged with glutamate.
Dantrolene pre-treatment protects YAC128 MSNs from
glutamate-induced toxicity
The deranged intracellular Ca
2+ signaling in HD MSNs
is linked to increased susceptibility to glutamate-induced
cell death [4-6,20-22]. Given that RyanRs appear to con-
tribute to the augmented intracellular Ca
2+ levels
observed in YAC128 MSNs in response to glutamate
(Figure 1), we hypothesized that blockade of the RyanRs
would attenuate the glutamate-induced toxicity in
YAC128 MSNs. To test this hypothesis, we treated both
YAC128 and WT MSNs (14DIV) with dantrolene, a
blocker of RyanR activity, prior to the application of 250
μM glutamate, a concentration shown to induce MSN
apoptosis in an in vitro model of HD [4-6,20-22]. As we
reported previously [4-6,20-22], in the absence of gluta-
mate, there was no significant difference between the
percentage of apoptotic neurons in YAC128 and WT
M S Nc u l t u r e s( T a b l e1 ) .A f t e re x p o s u r et o2 5 0μMg l u -
tamate, the percentage of apoptotic neurons in YAC128
MSN cultures was increased significantly when com-
pared to WT cultures (Table 1, Control 1 and Control 2
groups). To assess the neuroprotective effects of dantro-
lene, MSNs were pretreated for 1 h with various con-
centrations of dantrolene (10 nM - 50 μMr a n g e )a n d
after the application of 250 μM glutamate, the percen-
tage of apoptotic neurons was determined by terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL). We found that 0.01 μM dantrolene had no
significant effects on the glutamate-induced apoptosis of
YAC128 MSNs (Figure 2A, Table 1); 0.1 μMa n d1μM
dantrolene showed partial rescue of YAC128 MSNs
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Page 2 of 12treated with glutamate (Figure 2B, C, Table 1); and 10
μMa n d5 0μM dantrolene was able to prevent most
YAC128 MSNs from glutamate-induced toxicity (Figure
2D, Table 1). Interestingly, dantrolene treatment was
not able to rescue WT MSNs from glutamate-induced
toxicity (Figure 2, Table 1), suggesting that RyanRs do
not play a significant role in the glutamate-induced
apoptosis of WT cultures. These data demonstrate that
the CICR Ca
2+ release from RyanRs play a significant
and specific role in mediating the increased glutamate-
induced cell death observed in YAC128 MSNs and that
dantrolene treatment is effective in protecting YAC128
MSNs from glutamate toxicity.
Dantrolene rescues the motor coordination deficiencies in
YAC128 mice
Dantrolene can be considered a general Ca
2+ signaling
stabilizer. The neuroprotective characteristics of dantro-
lene have been shown in glutamate toxicity assay with
YAC128 MSNs (Figure 2, Table 1) and in previously
reported experiments with cultured neuronal cells and
animal models of excitotoxicity [23-31]. We recently
reported that dantrolene was neuroprotective in mouse
models of SCA2 and SCA3 [18,19]. These results lead
us to evaluate the potential beneficial effects of dantro-
lene in the YAC128 HD mouse model. For these studies,
5 mg/kg of dantrolene in phosphate buffered saline
(PBS) and corn flour was orally delivered to YAC128
and WT mice twice a week from 2 months of age until
all the mice were 11.5 months of age, followed by a
w a s h o u tp e r i o do f2m o n t h s( 1 3 . 5m o n t h so fa g e ) .T h e
control groups of WT and YAC128 mice were fed with
PBS and corn flour alone. Behavioral assessment of all
four groups of mice was performed using the “beam-
walk” assay. Basal beam-walking performance was deter-
mined before the initiation of dantrolene feeding at 2
months of age. Beam-walking performance data were
collected at 2, 4, 7, 9.5, 11.5, and 13.5 (washout) months
of age. As in our previous studies with YAC128 HD
mice [5,32,33], three kinds of beams (17 mm round, 11
mm round, and 5 mm square) were used for testing.
The “latency” and “number of foot slips” were for each
mouse determined on each beam.
Consistent with our previous findings [5,32,33], we
found that with age the PBS-fed group of YAC128 mice
exhibited a progressive impairment in beam-walking
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Figure 1 Caffeine potentiates glutamate-induced Ca
2+ signals in YAC128 and WT MSN cultures. Representative 340/380 nm Fura-2 ratio
traces are shown for YAC128 (red) and WT (green) after application of 2.5 μM glutamate (A), 2.5 mM caffeine (B), and 2.5 μM glutamate + 2.5
mM caffeine simultaneously (C). The average differences between the peak ratio and base line ratio for each treatment was calculated and
shown as mean ± SE, n = number of cells (D). *p < 0.05 compared to corresponding genotype treated with 2.5 μM glutamate only,
#p < 0.05
comparing YAC128 to WT, and ns = not significant using one-way ANOVA with Tukey’s post test. WT, wild type; YAC, YAC128; glu, glutamate.
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Page 3 of 12ability, resulting in longer beam traverse latencies and
increased number of foot slips, compared to the WT
PBS-fed group (Figure 3). These impairments in
YAC128 mice became more evident as beam difficulty
increased (Figure 3). Significant differences (p <0 . 0 5 )
between the beam-walking performance of control
YAC128 and control WT groups were observed at 11.5
and 13.5 months of age on the 17 mm round beam
Table 1 Effects of dantrolene on glutamate-induced apoptosis in WT and YAC128 MSN.
Dantrolene treatment WT (% TUNEL-positive) YAC128 (% TUNEL-positive)
0 μM glutamate 250 μM glutamate 0 μM glutamate 250 μM glutamate
Control 1 5.20 ± 1.16 32.22 ± 2.66 5.94 ± 1.11 57.45 ± 5.62
0.01 μM 7.45 ± 1.08 32.02 ± 2.28 7.13 ± 1.37 52.03 ± 5.45
0.1 μM 4.92 ± 1.48 31.36 ± 3.64 5.73 ± 0.87 40.37 ± 3.18*
Control 2 16.43 ± 1.25 37.43 ± 3.66 17.05 ± 1.18 73.26 ± 3.32
1.0 μM 14.05 ± 0.68 37.61 ± 2.75 21.76 ± 2.60 50.45 ± 4.11***
10 μM 17.22 ± 1.39 34.69 ± 1.86 18.75 ± 1.92 42.79 ± 2.85***
50 μM 17.94 ± 0.95 38.20 ± 2.21 19.73 ± 1.67 35.85 ± 2.24***
***p < 0.001 compared to Control 2, *p < 0.05 compared to Control 1 using one-way ANOVA with Tukey’s post test.
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Fi 2 Figure 2 Dantrolene protects YAC128 MSNs from glutamate-induced apoptosis. Quantification of glutamate-induced apoptotic cell death
of cultured 14DIV YAC128 (closed) and WT (open) MSNs, with (red) or without (black) 1 h dantrolene (Dan) pre-treatment. Shown are the mean
± SE of % TUNEL positive cells = (number of TUNEL positive MSNs/number of MSNs) × 100%. n = number of fields counted, Stats. WT, wild
type; Q128, YAC128.
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Page 4 of 12(Figure 3B); at 7, 9.5, 11.5 and 13.5 months of age on 11
mm round beam (Figure 3C, D) and at 7, 9.5, 11.5 and
13.5 months of age 5 mm square beam (Figure 3E, F).
Dantrolene feeding had no significant effect on the
beam-walk performance of the WT mice (Figure 3,
black data points). However, feeding dantrolene to
YAC128 mice improved their beam-walking perfor-
mance significantly (p < 0.05) by shortening the beam
traverse latencies and decreasing the number of foot
slips (Figure 3, red data points). Significant differences
(p < 0.05) in latency between the dantrolene-fed
YAC128 group and the YAC128 control group were
detected at 11.5 and 13.5 months of age on 17 mm
round beam (Figure 3A) and 11 mm round beam (Fig-
ure 3C), and at 9.5, 11.5, 13.5 months of age on 5 mm
s q u a r eb e a m( F i g u r e3 E ) .A t7 ,9 . 5 ,1 1 . 5 ,a n d1 3 . 5
months of age, the number of foot slips of dantrolene-
fed YAC128 mice on all three beams were very similar
to control WT mice (Figure 3B, D, F). We noticed that,
after dantrolene withdrawal, the performance of both
WT and YAC128 groups of mice was impaired, with
increased latencies and elevated numbers of foot slips
(Figure 3). This phenomenon is most likely to be attrib-
uted to the removal of the sedative effect of dantrolene,
which resulted in the increased anxiousness of the mice.
Despite this “withdrawal effect” the dantrolene-fed
YAC128 mice still performed significantly better than
control YAC128 mice in most tasks 13.5 months of age
(Figure 3). While conducting beam-walking assays, we
observed that some aging mice exhibited periods of
“crawling behavior”, defined as prolonged contact
between the thorax and abdomen of the mice and beam
surface, with the mice using their fore-limbs to drag
themselves along the beam. One mouse in the YAC128
control group crawled on the 11 mm round beam at
11.5 and 13.5 months of age and one mouse in the
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Figure 3 Dantrolene feeding improves performance of YAC128 mice in the beam-walk test. Motor coordination performance of WT and
YAC128 mice in dantrolene trial. A-F. Beam walk assay. The average time to cross the beam (A, C, E) and the average number of foot slips on
the beam (B, D, F) are shown for beam-walking experiments performed with 17 mm round plastic beam (A, B), 11 mm round plastic beam (C,
D), and 5 mm square wood beam (E, F). The data for WT control mice (open black circles), YAC128 control mice (open red circles), WT mice fed
with dantrolene (filled black circles), and YAC128 mice fed with dantrolene (filled red circles) are shown as mean ± SE (for the numberof mice
(10) in each experimental group, see Table 2) 2, 4, 7, 9.5, 11.5, and 13.5 (washout) months of age. While counting the foot slips of the mice with
“crawling behavior, “ we considered every step as one foot slip. *p < 0.05, significant differences between control WT group and control SCA3
group. “xF” on C and E mouse fell off the beam and failed the test where x = number of mice. *p < 0.05 using one-way ANOVA with Tukey’s
post test. WT, wild type; YAC, YAC128; Ctrl, control; Dan, dantrolene.
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Page 5 of 12YAC128 control group crawled on 5 mm square beam
at 13.5 months of age. Some mice fell off of the beam
during testing. Two mice in the YAC128 control group
fell off of the 11 mm round beam when tested at 11.5
and 13.5 months of age (Figure 3C). For the test on 5
mm square beam, one mouse fell off at 9.5 months of
age, 2 mice fell off at 11.5 months of age, and 4 mice
fell off at 13.5 months of age (Figure 3E). In contrast,
none of the mice in the WT groups and the dantrolene-
fed YAC128 group exhibited crawling behavior or fell
off the beams at any age tested. The incidence of crawl-
ing behavior was consistent with the general perfor-
mance of these mice in beam-walk assay, with the
YAC128 control group performing the worst, dantro-
lene-fed YAC128 group performing better, and the WT
groups performing the best.
At the conclusion of the beam-walking behavioral
experiments (13.5 months of age), we assessed gait
abnormalities in the four groups of mice by footprint
pattern analysis (Figure 4). The footprint patterns
were assessed quantitatively by the measurements of
stride length and front/hind footprint overlap as we
previously described for YAC128 HD mice [5,32,33].
Consistent with our previous findings [5,32,33], the
stride length of YAC128 PBS-fed mice was signifi-
cantly (p < 0.05) shorter than WT PBS-fed mice (Fig-
ure 4A, B). Dantrolene feeding significantly increased
the stride length of YAC128 mice, but had no
obvious effects on stride length of WT mice (Figure
4A, B). We further found that front/hind footprint
overlap was significantly higher in YAC128 control
group than in WT control group and feeding dantro-
lene to YAC128 mice alleviated the footprint overlap
deficit (Figure 4A, C). These data demonstrate that
dantrolene feeding can rescue the motor coordination
deficits observed in YAC128 mice, suggesting that
striatal function is regained and/or preserved by
dantrolene.
Dantrolene feeding reduces NeuN-postitive cell loss in
striata of YAC128 mice
To further evaluate the potential neuroprotective
effects of dantrolene in the striata of the experimental
mice we determined brain weight and counted MSNs
by an unbiased stereology approach. Our analysis was
focused on the striatal region because it is severely
affected in HD patients and we show that dantrolene
treatment is neuroprotective for YAC128 MSNs in
vitro (Figure 2, Table 1). At the conclusion of beha-
vioral analysis (14 months of age), mice from all four
groups were perfused transcardially with 4% parafor-
maldehyde in PBS and the brains were extracted and
weighed. We found that the brains of control YAC128
mice weighed significantly (p < 0.05) less than the
brains of control WT mice (Figure 5A). Feeding dan-
trolene to WT mice had no significant effect on the
brain weight of these mice (Figure 5A, Table 2). How-
ever, feeding dantrolene to YAC128 mice increased
brain weight compared to control YAC128, though the
difference was not statistically significant (Figure 5A,
Table 2). Importantly, long-term feeding of dantrolene
did not induce general toxicity in WT or YAC128
mice by pathological assessment of muscle, heart and
liver tissues (Table 3).
To obtain quantitative information about neuronal
loss in the experimental mice, we stained the striatal
slices for NeuN, a nuclear-specific marker of mature
neurons (Figure 5B), and performed stereological analy-
sis. NeuN-positive neurons in each striatum were
counted blindly with respect to the nature of slices (gen-
otype and drug treatment). Consistent with our previous
findings [5,32,33], we determined that PBS-fed YAC128
mice showed significant neuronal loss in the striatum (p
< 0.05) when compared with PBS-fed WT mice (Figure
5C, Table 2). We further found that dantrolene feeding
had no significant effect on NeuN-positive counts in the
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Figure 4 Dantrolene feeding improves gait abnormalities in
YAC128 mice. Gait analysis of WT and YAC128 mice in dantrolene
trial. (A). The footprint patterns of 13.5-month-old WT and YAC128
for control and dantrolene groups are shown. (B) Stride lengths
(cm) and (C) front/hind footprint overlaps (cm) of WT and YAC128
mice in dantrolene trial are shown as mean ± SE (n = number of
mice (10) in each groupsee Table 2), *p < 0.05 using one-way
ANOVA with Tukey’s post test. WT, wild type; YAC, YAC128; Ctrl,
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Page 6 of 12striata of WT mice but significantly increased NeuN-
positive counts (p < 0.05) in YAC128 mice (Figure 5C,
Table 2). The data show that dantrolene feeding pro-
tected against the age-dependent loss of NeuN-positive
neurons in the striata of YAC128 mice.
Dantrolene feeding inhibits the aggregation of Htt
exp in
the striata of YAC128 mice
Given that Htt
exp aggregation is thought to induce the
progressive and selective death of striatal MSNs [1,2],
we wanted to determine if dantrolene feeding could pre-
vent or inhibit the aggregation of Htt
exp and provide a
potential mechanism of neuroprotection in YAC128
mice. Using brain slices from mice representing all 4
treatment groups (Figure 5, Table 2), we stained for
aggregated Htt
exp, where positive staining for aggregated
Htt
exp appears dark gray due to the nickel in the detec-
tion medium. Nuclei were counterstained with cresyl
violet. Consistent with previous findings [34], PBS-fed
YAC128 mice showed significant Htt
exp aggregation in
striatal cells, indicated by dark and condense staining in
the nucleus, as compared to PBS-fed WT (Figure 6).
Interestingly, dantrolene-fed YAC128 mice showed a
weaker and distributed staining, which suggests that
dantrolene dramatically reduced the degree of Htt
exp
aggregation in striatal cells as compared to PBS-fed
YAC128. Striatal cells from dantrolene-fed WT mice
appeared similar to cells from control mice (Figure 6).
These observations suggest that dantrolene feeding may
significantly reduce the amount of Htt
exp nuclear aggre-
gation in striatal neurons of YAC128 mice.
Discussion
In our previous studies we demonstrated that abnormal
neuronal Ca
2+ signaling plays a significant role in the
pathogenesis of HD and other polyQ expansion disor-
ders [3-6,18-20,32,35]. We have also found that the Ca
2+
stabilizer and RyanR antagonist, dantrolene, was neuro-
protective in the mouse models of polyQ expansion dis-
orders SCA2 and SCA3 [18,19]. The data in the present
study point to the role of RyanRs in the exaggerated Ca
2
+ response to glutamate observed in MSNs from the
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groupsee Table 2). (B) The striatal slices from 14 months old control
(PBS-fed) and dantrolene-fed WT and YAC128 mice were stained by
the neuronal nuclear marker NeuN. Representative images are
shown. (C) Striatal cell counts obtained as a result of stereological
analysis of NeuN-stained striatal slices from 14 months old control
(PBS-fed) and dantrolene-fed WT and YAC128 mice. The MSN
numbers are shown as mean ± SE (n = number of mice, see Table
2). ***p < 0.001, *p < 0.05 using one-way ANOVA with Tukey’s post
test. WT, wild type; YAC, YAC128; Ctrl, control; Dan, dantrolene.
Table 2 Brain weight and MSN counts of 14 months old
WT and YAC128 mice.
Group
name
Number of female
mice
Brain weight
(g)
MSN counts
(10
6)
WT-Ctrl 10 0.499 ± 0.01 1.27 ± 0.03
WT-Dan 10 0.495 ± 0.01 1.263 ± 0.03
YAC128-Ctrl 10 0.437 ± 0.01*** 0.997 ± 0.03*
YAC128-
Dan
10 0.461 ± 0.01 1.18 ± 0.030
#
The brain weight and MSN counts from NeuN staining and stereological
analysis are shown as mean ± SE. ***p < 0.001, *p < 0.05 compared to WT-Ctrl
and
#p < 0.05 compared to YAC128-Ctrl using one-way ANOVA with Tukey’s
post test.
Pathological analysis of WT and YAC128 mice tissues following dantrolene
trial.
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Consistent with our in vitro findings, we showed that
long-term feeding of dantrolene to YAC128 mice signifi-
cantly (p < 0.05) alleviated age-related motor coordina-
tion deficits (Figure 3, 4) and prevented NeuN-positive
neuronal loss (p < 0.05) (Figure 5, Table 2) while leaving
WT control mice and neurons intact. Finally, dantro-
lene-fed YAC128 mice showed less Htt
exp nuclear aggre-
gation in striatal cells compared to control YAC128
mice (Figure 6), further supporting neuroprotective
effects of dantrolene treatment. These data provide
further support for the significant role of disturbed
intracellular Ca
2+ signaling in the pathogenesis of polyQ
expansion diseases and offer a potential, and clinically
relevant, drug for the treatment of HD.
Our laboratory has elucidated the interaction between
Htt
exp and InsP3R1 as well as other Ca
2+-related
mechanisms relevant to HD (for reviews, see [13-16]).
Based on these results we argued that the modulation of
intracellular Ca
2+ signaling is a viable approach in our
pursuit of disease-modifying therapies for HD. We first
discovered that Htt
exp binds directly and specifically to
the C-terminus region of InsP3R1 and that this interac-
tion is important for the augmented activity of the recep-
tor in planar lipid bilayers and in cultured MSNs [3]. We
then confirmed that MSNs from YAC128 HD mice had
disturbed IP3R-mediated Ca
2+ signaling which lead to
glutamate-induced apoptosis in YAC128 MSNs [4]. In a
more recent study we demonstrated pathological
enhancement of neuronal store-operated Ca
2+ entry
(SOC) pathway in HD [6]. In addition, increased Ca
2+
i n f l u xv i ae x t r a s y n a p t i cN R 2 Bs u b u n i to fN M D A Rw a s
proposed to play an important role in excitotoxic cell
death of HD MSN neurons [4,7-12]. The CICR mechan-
ism supported by RyanR can amplify the signal from
other Ca
2+ sources such as InsP3R1 and NMDARs. Per-
haps the effectiveness of dantrolene to reduce or block
glutamate-induced apoptosis in YAC128 MSN cultures
(Figure 2, Table 1) is attributed to the fact that by inhibit-
ing the RyanRs alone, both glutamate signaling pathways
important for inducing toxicity are blunted at the same
time, leading to robust neuroprotection. In addition to
RyanR, dantrolene may also inhibit neuronal SOC path-
way [36], which may also contribute to neuroprotective
effects of dantrolene observed in our experiments [6].
T h e r ea r ed r u g sa v a i l a b l et oh e l pm a n a g et h ec l i n i c a l
symptoms of HD but currently there is no treatment to
stop or reverse the course of the disease. The only drug
approved by the US Food and Drug Administration to
specifically treat HD is tetrabenazine (TBZ), an inhibitor
of the vesicular monoamine transporter that alleviates
chorea. Therefore, a notable finding of our study is that
long-term feeding of dantrolene to YAC128 mice was
able to prevent neurodegeneration in the striatum (Fig-
ure 5), reduced accumulation of Htt
exp muclear aggre-
gates (Figure 6) and significantly improve the motor
coordination deficiencies (Figure 3, 4) that are charac-
teristic to this model and HD pathogenesis. In motor
coordination assays the benefits of dantrolene feeding to
YAC128 mice were similar to the benefits of TBZ feed-
ing that we evaluated previously [32,33]. Thus, it can be
expected that dantrolene or other similar RyanR inhibi-
tors may result in significant clinical benefits for HD
patients.
Many studies have brought to light the neuroprotec-
tive properties of dantrolene (for recent review, see
Table 3 Pathological analysis of WT and YAC128 mice tissues following dantrolene trial.
Group name Number of mice analyzed No. of mice per group with any degree of inflammation
muscle heart liver
WT Ctrl 60 0 6
YAC128 Ctrl 40 1 4
WT Dan 30 0 3
YAC128 Dan 60 1 6
YAC128 WT
Ctrl
Dan
Figure 6 Dantrolene feeding inhibits Htt
exp aggregation in
YAC128 striatal cells. The striatal slices from 14 months old control
(PBS-fed) and dantrolene-fed WT and YAC128 mice were stained with
an anti-Htt monoclonal antibody (dark grey). Nuclei were counter-
stained with cresyl violet (blue). Representative images of 3 mice are
shown. WT, wild type; YAC, YAC128; Ctrl, control; Dan, dantrolene.
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Page 8 of 12[37]). For example, in cultured cortical neurons, dantro-
lene reduced the glutamate-induced increases in intra-
cellular Ca
2+-concentrations by 70% under physiologic
conditions, and protected against glutamate-induced
neurotoxicity [23]. The short-term delivery of dantro-
lene has been demonstrated previously to be neuropro-
tective in acute excitotoxicity paradigms, such as
cerebral ischemia [26,38] and a kainic acid injection
model [24,28,30]. It has also been demonstrated that
dantrolene can prevent apoptosis in neurons by amelior-
ating poly(ADP-ribose) polymerase (PARP)-related bioe-
nergetic failure during DNA repair in rat brain [39] and
up-regulating anti-apoptosis proteins such as Bcl-2 in
different cell lines [40,41]. We have previously demon-
strated the beneficial effects of long-term dantrolene
treatment in SCA2 and SCA3 genetic mouse models
[18,19]. Data from such studies has inspired researchers
to consider the utility of dantrolene as treatment for
many neurodegenerative diseases, including Alzheimer
disease (AD) [42,43], amyotrophic lateral sclerosis [44],
and ataxia [18,19] (for recent review [45]). However, in
our experiments we found that long-term feeding of
dantrolene to a mouse model of AD actually exacer-
bated the neuropathology related to the disease [46].
Dantrolene has been used safely in the clinic for decades
as treatment for malignant hyperthermia, but is also
used to manage neuroleptic malignant syndrome, mus-
cle spasticity, 3, 4-methylenedioxy methylamphetamine
("ecstasy”) intoxication, serotonin syndrome, and 2, 4-
dinitrophenol poisoning [47]. However, dantrolene can
also induce significant side effects, ranging from transi-
ent muscle weakness to more severe respiratory failure
[47] in both acute and chronic treatment regimens. In
our experiments, we saw a neuroprotective effect at 5
m g / k g ,w h i c hi sc o m p a r a b l et ot h ee f f e c t i v ed o s eo f2 . 4
mg/kg in healthy volunteers who experienced dizziness
and muscle weakness [47]. We have not observed signif-
icant toxic effects of dantrolene after pathological exam-
ination of skeletal mucle, heart and liver of WT and
YAC128 mice fed with dantrolene (Table 3).
Conclusions
Obtained results provide further support to the “Ca
2+
hypothesis of HD” [13-16] and highlight similarities in
the pathogenesis of HD, SCA2 and SCA3 [18,19,48,49].
Our data also implicate RyanRs as a potential therapeu-
tic target for the treatment of these disorders. Moreover,
our results indicate that RyanR inhibitors and Ca
2+ sig-
naling stabilizers such as dantrolene should be consid-
ered as potential therapeutics for the treatment of HD
and other polyQ-expansion disorders. It is not clear
however if dantrolene has a safety profile that allows for
its long-term use in clinic. The effect of chronic low
dose administration of dantrolene in humans is not
known and further study is required to determine if
dantrolene is an appropriate clinical tool for HD and
other polyQ expansion disorders.
Methods
Primary medium spiny neuron (MSN) cultures
All animal studies were approved by the University of
Texas Southwestern Medical Center Animal Care and
Use Committee. YAC128 transgenic mice (FVBN/NJ
background strain) were obtained from Jackson Labs
(stock number 004938) and breeding of YAC128 mice
was previously described [50]. Briefly, heterozygous male
YAC128 mice were crossed with the wild type (WT)
female mice and the resulting litters were collected on
postnatal days 1-2. The pups were genotyped by PCR
with primers specific for exons 44 and 45 of human
HTT and MSN cultures of WT and YAC128 mice were
established as described previously [4,7,20,32]. Briefly,
cultures were grown on poly-L-lysine (Sigma) coated 12
mm round coverslips (Assistent) in Neurobasal-A med-
ium supplemented with 2% B27, 1 mM L-glutamine and
penicillin-streptomycin (Invitrogen). Cultures were incu-
bated at 37°C in a 5% CO2 environment.
Ca
2+ imaging experiments
Fura-2 Ca
2+ imaging experiments were performed as
previously described [4]. The MSN cultures were
maintained until 10 days in vitro (DIV) and then
loaded with 5 μMF u r a - 2 A M( I n v i t r o g e n )i na r t i f i c i a l
cerebral spinal fluid (aCSF) (140 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 2 mM CaCl2 and 10 mM HEPES at
pH 7.3) for 45 min at 37°C. For imaging experiments,
the coverslips were mounted onto a recording chamber
(RC-26G; Warner Instruments) that was maintained at
37°C (PH1; Warner Instruments) and positioned on an
Olympus IX-70 inverted microscope. Before measure-
ments were taken, the coverslips were washed exten-
sively with Ca
2+-free aCSF (CaCl2 was replaced with
100 μME G T A ) .F o rC a
2+ imaging experiments, the
MSN cells were intermittently excited by 340 and 380
nm UV light using DeltaRAM illuminator (Photon
Technology International (PTI)), and the 510 nm
emitted light was collected by an IC-300 camera (PTI).
Images were collected using a 60× UV-grade oil
immersion objective (Olympus), then digitized and
analyzed by ImageMaster Pro software (PTI). Baseline
(1 min) measurements were obtained before bath
application of 2.5 μM glutamate and/or 2.5 mM caf-
feine dissolved in Ca
2+-free aCSF. Images at 340 and
380 nm excitation wavelengths were captured every 5 s
and shown as 340/380 image ratios at the time points
as indicated. Background fluorescence was determined
according to the recommendations of the manufacturer
(PTI) and subtracted.
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The in vitro cell death assay was performed as described
previously for MSN cultures [4,5,20]. Dantrolene was
added to the 14 DIV MSN cultures at 0.0, 0.1, 1, 10 or
50 μM. After 1 h incubation, 250 μM glutamate in Neu-
robasal-A was added to the culture medium and MSNs
were maintained in a cell culture incubator (humidified
5% CO2, 37°C) for 7 h. Immediately after glutamate
treatment, neurons were fixed for 30 min in 4% parafor-
maldehyde plus 4% sucrose in PBS (pH 7.4), permeabi-
lized for 5 min in 0.25% Triton X-100, and assayed for
apoptosis using the DeadEnd Fluorometric TUNEL Sys-
tem (Promega) according to manufacturer’s instructions.
Nuclei were counterstained with 5 μM propidium iodide
(PI) (Molecular Probes). Coverslips were washed with
PBS and mounted in Mowiol 4-88 (Polysciences). Fluor-
escein isothiocyanate (FITC)- and PI-fluorescent images
were collected with an Olympus IX70 microscope using
a 40× objective, a Cascade: 650 camera (Roper Scienti-
fic), and METAFLUOR software (Universal Imaging,
Downingtown, PA). Four to six randomly chosen micro-
scopic fields containing 200-300 MSN were captured.
The percentage of TUNEL-positive cells was determined
by taking the cell number of TUNEL-positive MSNs
and dividing by the total number of MSNs (or PI
stained neurons) × 100%. The percentage of TUNEL-
positive cells was among all the fields per treatment was
averaged and presented as the mean ± SE (n = number
of fields counted). The nuclei of glial cells, identified by
their large size and weak PI staining, were not counted
in the analysis.
Drug delivery in mice
Dantrolene was fed to mice as we described previously
in a tetrabenzine trial in YAC128 mice [33] and dantro-
lene trials in SCA3-YAC-84Q [19] and SCA2-58Q mice
[18]. Briefly, groups of 10 WT mice and 10 YAC128
mice were fed 100 μg of dantrolene suspended in 50 μl
of PBS with 2% corn flour resulting in a dosage of 5
mg/kg. The control groups (10 WT and 10 YAC128)
were fed with 2% corn flour in PBS. All mice were fed
orally twice per week from 2 to 11.5 months of age.
Motor coordination assessments in mice
The motor coordination experiments were performed as
we described previously in a tetrabenzine trial in
YAC128 mice [33] and dantrolene trials in SCA3-YAC-
84Q [19] and SCA2-58Q mice [18]. The “beam-walking”
a s s a yw a sp e r f o r m e du s i n gah o m e m a d ee x p e r i m e n t a l
setup. The 17 mm round plastic beam, 11 mm round
plastic beam, and 5 mm square wood beam were used
in our studies. At each time point, the mice were
trained on the beams for 3 consecutive days (four trials
per day) to traverse the beam into the enclosed box.
Once a stable baseline of performance was obtained, the
mice were tested in three consecutive trials on the 17
and 11 mm round plastic beams and the 5 mm square
wood beam, progressing from the widest to the narrow-
est beam. The latency to traverse the middle 80 cm of
each beam and the number of times the hind-paws
slipped off each beam were recorded for each trial. The
mean scores for each beam at a particular time point
were used in the analysis. For the footprint test, the
forepaws and hindpaws of the mice were coated with
purple and green non-toxic paints, respectively. The
mice were trained to walk along a paper-covered runway
that was 50 cm long, 10 cm wide, with 10 cm high walls
into an enclosed box. All the mice were given three
runs per day for 3 consecutive days. A fresh sheet of
white paper was placed on the floor of the runway for
each run. The footprint patterns were assessed quantita-
tively by the measurements of stride length and fore-
paw/hind-paw overlap as we described previously
[19,32].
Neuropathological assessments in mice
The neuropathological assessments were performed as
previously described [19,32]. After all the behavioral
tests (14.5 month time point), the mice were terminally
anesthetized by ketamine/xylazine and perfused trans-
cardially with PBS then 4% paraformaldehyde in 0.1 M
PBS, pH 7.4 as before [19,32]. All brains were removed,
weighed, transferred to post-fixative (4% paraformalde-
hyde) for 24 h at 4°C, and equilibrated in 20-30% (w/v)
sucrose in PBS for 24-48 h 4°C. The brains were pro-
cessed and cut into 30 μm-thick coronal sections using
a SM2000R sliding microtome (Leica, Bannockburn, IL).
Coronal sections spaced 360 μm apart throughout the
striatum (in the range from +1.70 mm to -2.30 mm rela-
tive to bregma) were collected. For the quantification of
neuronal loss, sections were stained with anti-NeuN
monoclonal antibody (1:1000 dilution; Millipore, Biller-
ica, MA). Biotinylated anti-mouse IgG reagent was used
as the secondary antibody (1:250 dilution; M.O.M. kit,
Vector Laboratories). Signal was amplified with an ABC
Elite kit (Vector Laboratories) and detected with diami-
nobenzidine (DAB) (Vector Laboratories). For the detec-
tion of Htt
exp protein aggregation, sections were stained
with anti-Htt monoclonal antibody (1:200 dilution:
Millipore), amplified and detected as before, and coun-
ter-stained with cresyl violet. The stained sections were
mounted with Dako Glycergel Mounting Medium
(Dako) onto the slides. All quantitative stereological
analyses were performed blindly with respect to the nat-
ure of slices (genotype and drug feeding) using the
Stereo Investigator setup and software (MicroBrightField
Inc., Williston, VT). All quantitative stereological ana-
lyses were performed blindly with respect to the nature
Chen et al. Molecular Neurodegeneration 2011, 6:81
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tigator. The grid size was set to 450 × 450 μm, and the
counting frame was set to 50 × 50 μm. The average
slice thickness after histological processing was deter-
mined to be 22 μm.
Pathological analysis
Before perfusion, a hind-leg with fresh skeletal muscle
was taken from each terminally anesthetized mouse.
After perfusion and removal of the brain, the mouse
carcasses were fixed in 10% buffered formalin until dis-
sected. Representative sections of the heart, liver, lung
and skeletal muscle samples from half of the animals in
each group were obtained. Tissue was embedded in par-
affin blocks, sectioned at 4 μm thickness, stained with
hematoxylin and eosin, and coverslipped for light micro-
scopic evaluation. The presence and degree of lympho-
cytic infiltrates in the four tissue types was semi-
quantitatively graded using the following schema: 0, no
inflammation; 1, rare, scattered, small collections of lym-
phocytes; 2, occasional scattered collections; and 3, fre-
quent large collections.
Statistical data analysis
For comparison between two or more groups, ANOVA
with post hoc testing was used to statistically analyze
data.
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